Thymosin Alpha-1 dosing & administration
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
1.6 mg
Frequency
Twice weekly (3-4 days apart)
Duration
6-12 months
Timing
Best time to take
Morning or early afternoon injections work well for most people. Some prefer morning to align with natural cortisol rhythms and immune activity peaks.
With food?
Can be taken regardless of food. Thymosin Alpha-1 absorption isn't significantly affected by meals, so fit it into whatever schedule works best for you.
If stacking
If using with other peptides like BPC-157, inject at separate sites. Thymosin Alpha-1 works well alongside Thymalin for comprehensive immune support. Space injections at least a few hours apart when stacking.
Adjusting your dose
Increase if
- You've tolerated the starting protocol well for 4+ weeks
- Your healthcare provider recommends intensification for specific conditions
- Blood work shows continued immune markers that could benefit from support
Decrease if
- You experience persistent flu-like symptoms beyond the first week
- Injection site reactions don't improve with site rotation
- You develop signs of immune overstimulation (discuss with doctor)
- Any autoimmune symptoms emerge or worsen
Signs of right dose
- Fewer colds and infections over time
- Faster recovery when you do get sick
- Stable energy levels
- Improved lab markers if tracking immune function
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—this is how it was used in all major clinical trials and provides reliable absorption
Best sites
Storage
Before reconstitution
Keep lyophilized powder refrigerated at 36-46°F (2-8°C) for up to 2 years. For longer storage, freeze at -4°F (-20°C). Always store in original vial away from light. Room temperature is acceptable for short shipping periods but refrigerate upon receipt.
After reconstitution
Refrigerate at 36-46°F (2-8°C) immediately after mixing. Never freeze reconstituted solution—ice crystals can damage the peptide. Keep away from light. Use within 14-21 days for best potency.
Signs of degradation — discard the vial
Sample daily schedule
Morning (8-10 AM) on consistent days
1.6 mg injection
Site: Rotate between abdomen, thigh, and arm
Most protocols use twice-weekly injections on fixed days (e.g., Monday/Thursday or Tuesday/Friday). Consistency helps maintain stable immune support. Rotate injection sites each time to prevent irritation.
Safety
Is it safe?
Side effects
Commonly reported: Injection site reactions, Mild fatigue, Flu-like symptoms
Less common: Mild fever, Lymph node awareness
Stop and seek help if
- Any signs of allergic reaction—stop immediately and seek medical help
- Worsening of any autoimmune symptoms you may have
- Persistent fever above 101°F that doesn't resolve
- Severe or spreading injection site reactions
- Any new symptoms that concern you or feel abnormal
- Completion of your prescribed treatment cycle
Thymosin Alpha-1 is approved for specific uses in some countries but remains a research compound for other applications. Always work with a qualified healthcare provider when using any peptide therapy. This information is educational—not medical advice for your specific situation.
Flagged pairings
- Immunosuppressants (cyclosporine, tacrolimus) — CONTRAINDICATED. Thymosin Alpha-1 stimulates immune function, directly opposing these medications. Could trigger transplant rejection.
- Corticosteroids (prednisone) — May reduce Thymosin Alpha-1 effectiveness. If you need steroids, timing separation may help. Discuss with your doctor.
Published research
What the studies show
Garaci E, Pica F, Matteucci C · 2015
This comprehensive review showed that Thymosin Alpha-1 combined with chemotherapy improved outcomes in melanoma and lung cancer patients. The peptide works on both immune cells and tumor cells, making it uniquely valuable as a cancer adjunct therapy.
Romani L, Moretti S, Fallarino F · 2012
Researchers found that Thymosin Alpha-1 activates multiple immune pathways through Toll-like receptors, enhances dendritic cell function, and importantly activates the IDO enzyme which helps prevent harmful inflammation. This explains how it can both boost immunity AND prevent autoimmune overreaction.
Chen JF, Chen SR, Lei ZY · 2022
This randomized controlled trial of 120 patients showed that Thymosin Alpha-1 improved 90-day survival from 53% to 75% in severe liver failure patients. It also cut infection rates nearly in half and reduced hepatic encephalopathy risk. Major evidence for serious illness applications.
Ancell CD, Phipps J, Young L · 2001
This thorough review documented that Thymosin Alpha-1 cleared hepatitis B virus in 40% of treated patients versus only 9% of controls. For hepatitis C, combination with interferon achieved 65% viral clearance versus 29% with interferon alone. The 2-hour half-life and excellent safety profile were confirmed across all trials.
Clinical Trial NCT04428008 · 2023
This Phase 2 trial in 262 dialysis patients (who are highly vulnerable to infections) evaluated whether Thymosin Alpha-1 could prevent COVID-19 infection. The study completed, showing the continued interest in Thymosin Alpha-1 for vulnerable populations facing infectious threats.
Iino S, Toyota J, Kumada H, et al. · 2004
Studied for
Conditions Thymosin Alpha-1 has been researched in
Want the full picture?
The complete Thymosin Alpha-1 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.